{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:15:21Z","timestamp":1777932921056,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"f. hoffmann-la roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40273-021-01092-9","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T02:17:10Z","timestamp":1634523430000},"page":"91-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2952-150X","authenticated-orcid":false,"given":"Siu Hing","family":"Lo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7510-1127","authenticated-orcid":false,"given":"Ksenija","family":"Gorni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5488-1374","authenticated-orcid":false,"given":"C. Simone","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmina","family":"Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7597-6556","authenticated-orcid":false,"given":"Andrew","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3438-4853","authenticated-orcid":false,"given":"Noman","family":"Paracha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"issue":"2","key":"1092_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/338627","volume":"70","author":"M Feldkotter","year":"2002","unstructured":"Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70(2):358\u201368.","journal-title":"Am J Hum Genet"},{"issue":"9630","key":"1092_CR2","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH. Spinal muscular atrophy. Lancet (London, England). 2008;371(9630):2120\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(08)60921-6.","journal-title":"Lancet (London, England)."},{"key":"1092_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D'Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"1092_CR4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/0883073807305673","volume":"22","author":"BS Russman","year":"2007","unstructured":"Russman BS. Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol. 2007;22(8):946\u201351.","journal-title":"J Child Neurol"},{"key":"1092_CR5","unstructured":"Food and Drug Administration. Approval Package for Spinraza Injection, 2.4 mg\/mL. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/209531Orig1s000Approv.pdf. Accessed Oct 2021."},{"issue":"1","key":"1092_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/1060028018789956","volume":"53","author":"MK Claborn","year":"2019","unstructured":"Claborn MK, Stevens DL, Walker CK, Gildon BL. Nusinersen: a treatment for spinal muscular atrophy. Ann Pharmacother. 2019;53(1):61\u20139. https:\/\/doi.org\/10.1177\/1060028018789956.","journal-title":"Ann Pharmacother"},{"key":"1092_CR7","unstructured":"European Medicines Agency. Spinraza: EPAR\u2014Product Information. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spinraza-epar-product-information_en.pdf. Accessed Oct 2021."},{"key":"1092_CR8","unstructured":"Food and Drug Administration. EVRYSDI(R) Highlights of prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213535s000lbl.pdf. Accessed Oct 2021."},{"key":"1092_CR9","unstructured":"AveXis Inc. ZOLGENSMA (onasemnogene abeparvovec-xioi) [package insert]. Bannockburn, IL. 2019. https:\/\/www.fda.gov\/media\/126109\/download. Accessed Oct 2021."},{"issue":"1","key":"1092_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-020-01667-3","volume":"16","author":"A Monnette","year":"2021","unstructured":"Monnette A, Chen E, Hong D, Bazzano A, Dixon S, Arnold WD, et al. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis. 2021;16(1):36. https:\/\/doi.org\/10.1186\/s13023-020-01667-3.","journal-title":"Orphanet J Rare Dis"},{"key":"1092_CR11","unstructured":"EuroQol Research Foundation. EQ-5D-5L. 2021. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/. Accessed Oct 2021."},{"issue":"1","key":"1092_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"F Johnson","year":"2013","unstructured":"Johnson F, Lancsar E, Marshall D, Kilambi V, M\u00fchlbacher A, Regier D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3\u201313. https:\/\/doi.org\/10.1016\/j.jval.2012.08.2223.","journal-title":"Value Health."},{"issue":"4","key":"1092_CR13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"A Hauber","year":"2016","unstructured":"Hauber A, Marcos Gonz\u00e1lez J, Groothuis-Oudshoorn C, Prior T, Marshall D, Cunningham C, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300\u201315. https:\/\/doi.org\/10.1016\/j.jval.2016.04.004.","journal-title":"Value Health"},{"issue":"2","key":"1092_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/hec.1697","volume":"21","author":"E De Bekker-Grob","year":"2012","unstructured":"De Bekker-Grob E, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21(2):145\u201372. https:\/\/doi.org\/10.1002\/hec.1697.","journal-title":"Health Econ"},{"issue":"4","key":"1092_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403\u201313. https:\/\/doi.org\/10.1016\/j.jval.2010.11.013.","journal-title":"Value Health"},{"key":"1092_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02379.x","volume":"450","author":"WHO Multicentre Growth Reference Study Group","year":"2006","unstructured":"WHO Multicentre Growth Reference Study Group. WHO Motor Development Study: windows of achievement for six gross motor development milestones. Acta Paediatr Suppl. 2006;450:86\u201395. https:\/\/doi.org\/10.1111\/j.1651-2227.2006.tb02379.x.","journal-title":"Acta Paediatr Suppl"},{"issue":"7","key":"1092_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.nmd.2005.03.004","volume":"15","author":"C Berard","year":"2005","unstructured":"Berard C, Payan C, Hodgkinson I, Fermanian J. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005;15(7):463\u201370.","journal-title":"Neuromuscul Disord"},{"key":"1092_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625\u201335.","journal-title":"N Engl J Med"},{"key":"1092_CR19","unstructured":"Centre for Community-Driven Research (CCDR), SMA Australia, Muscular Dystrophy New South Wales, Muscular Dystrophy Western Australia, Muscular Dystrophy Queensland, Muscular Dystrophy Australia, et al. Patient Experience, Expectations and Knowledge: Spinal Muscular Atrophy Australian Study. PEEK. 2017."},{"key":"1092_CR20","unstructured":"Roche. Evrysdi (risdiplam) summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/evrysdi-epar-product-information_en.pdf. Accessed Oct 2021."},{"key":"1092_CR21","volume-title":"In frontiers in econometrics","author":"D McFadden","year":"1974","unstructured":"McFadden D. Conditional logit analysis of qualitative choice behavior. In: Zarembka P, editor. In frontiers in econometrics. New York: Academic Press; 1974."},{"key":"1092_CR22","volume-title":"Stata statistical software: release 16","author":"StataCorp,","year":"2019","unstructured":"StataCorp, . Stata statistical software: release 16. College Station: StataCorp LLC; 2019."},{"issue":"3","key":"1092_CR23","first-page":"388","volume":"7","author":"AR Hole","year":"2007","unstructured":"Hole AR. Fitting mixed logit models by using maximum simulated likelihood. Stand Genomic Sci. 2007;7(3):388\u2013401.","journal-title":"Stand Genomic Sci"},{"key":"1092_CR24","unstructured":"Office for National Statistics. National life tables, UK: 2014 to 2016. 2017. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/bulletins\/nationallifetablesunitedkingdom\/2014to2016. Accessed Oct 2021."},{"key":"1092_CR25","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200611","author":"M Walter","year":"2021","unstructured":"Walter M, Chiriboga C, Duong T, Goemans N, Mayhew A, La\u00ebtitia O, et al. Improving care and empowering adults living with SMA: a call to action in the new treatment era. J Neuromuscul Dis. 2021. https:\/\/doi.org\/10.3233\/JND-200611.","journal-title":"J Neuromuscul Dis."},{"issue":"1","key":"1092_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-020-1339-3","volume":"15","author":"HWY Wan","year":"2020","unstructured":"Wan HWY, Carey KA, D\u2019Silva A, Vucic S, Kiernan MC, Kasparian NA, et al. Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review. Orphanet J Rare Dis. 2020;15(1):70. https:\/\/doi.org\/10.1186\/s13023-020-1339-3.","journal-title":"Orphanet J Rare Dis"},{"key":"1092_CR27","unstructured":"EMA. ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi) EMA prescribing information. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zolgensma-epar-product-information_en.pdf. Accessed Oct 2021."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01092-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01092-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01092-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T15:19:54Z","timestamp":1649517594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01092-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":27,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1092"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01092-9","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"16 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by F. Hoffmann-La Roche Ltd, Basel, Switzerland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This article is published in a special edition journal supplement wholly funded by F. Hoffmann-La Roche Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement"}},{"value":"SHL and AL are employees of Acaster Lloyd Consulting Ltd, who were commissioned by F. Hoffmann-La Roche Ltd to conduct this study and therefore received a consulting fee to conduct the study presented in the article. CSS, YM and KG are employees of F. Hoffmann-La Roche Ltd. During the preparation of the manuscript, NP was employed by F. Hoffmann-La Roche. NP and KG are shareholders of F. Hoffmann-La Roche.\u00a0CSS is a shareholder of Roche Holding AG.\u00a0","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors adhere to <i>General Data Protection Regulation<\/i> (GDPR) and UK Data Protection requirements, so will not make individual de-identified participant data available, as no consent to share the data publicly has been obtained; however, the study protocol will be made available upon request to the corresponding author.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not available.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SHL and AL designed the study. SHL analyzed the data. SHL and AL interpreted the data and drafted the manuscript. NP and KG contributed to the design of the study, interpreted the data and revised the draft critically for important intellectual content. CSS and YM interpreted the data and revised the draft critically for important intellectual content. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This study was reviewed and received exempt status determination by an independent review board, the Western Institutional Review Board (WIRB), on 6 June 2019 (submission number: #1-1190961-1), prior to participant recruitment.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Freely given, informed consent to participate in the study was obtained from participants prior to participation in the study.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Freely given, informed consent for the scientific publication of the results of this research was obtained from participants prior to participation in the study.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}